(Q81071045)
Statements
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (English)
C Szczylik
B Melichar
P Koralewski
S Bracarda
C Chevreau
M Filipek
R Delva
E Sevin
S Négrier
J McKendrick
A Santoro
P Pisa